Molecular Partners AG
Nasdaq MOLN · Schlieren-Zurich, Switzerland
Works in Hematology · Infectious disease · Oncology · Respiratory
Molecular Partners AG is a clinical trial sponsor based in Schlieren-Zurich, Switzerland, listed as Nasdaq MOLN. It has 1 active clinical trial with 138 planned participants, in Hematology, Infectious disease, Oncology and Respiratory. Since 2021 it has completed 5 trials and stopped 3 early.
Trial track record · since 2021
Financials · Nasdaq MOLN
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Molecular Partners AG
Molecular Partners AG is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 138 planned participants, in Hematology, Infectious disease, Oncology, Respiratory. Since 2021 it has completed 5 trials and stopped 3 early.
Molecular Partners AG is based in Schlieren-Zurich, Switzerland and is listed as Nasdaq MOLN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Molecular Partners AG; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-21.
Approve Suite is not affiliated with Molecular Partners AG.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.